1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced): new trials by email Literature Review of Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced) trials Research Report on Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata Ruxolitinib - Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 70 | 2023-01-18 | 2026-06-22 |
Alopecia (1) · Alopecia Areata (1) · Polyendocrinopathies, Autoimmune (1)
Autoimmune Diseases (1) · Endocrine System Diseases (1) · Hair Diseases (1) · Hypotrichosis (1) · Immune System Diseases (1) · Pathological Conditions, Anatomical (1) · Pathological Conditions, Signs and Symptoms (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
ruxolitinib (1)
National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (1)